Special Issue: Anti-malarial drugs effects on Covid-19

An international group of researchers believe there is enough evidence that anti-malarial drugs could be repurposed to treat COVID-19. The usage of antimalarial drugs outlines the evidence for the antiviral and anti-inflammatory properties of some of these drugs that could play a role in tackling COVID-19.

Antimalarial drugs have been used for over 60 years in the treatment of malaria, amoebic liver abscess, and several rheumatological conditions, but their clinical pharmacology is not well understood. COVID-19 is a new potential indication, although these drugs have only moderate in vitro activity against the SARS-CoV-2 virus and there is no convincing evidence at this time of significant clinical efficacy.

Acknowledging the current situation regarding covid-19, how world and researchers fought to bring out a solution to overcome the pandemic, Journal of Drug Designing: Open Access is coming up with a special issue titled “Anti-malarial drug effects on Covid-19” which focuses on the topics related to the antimalarial drugs that have potential in treating Covid-19.

We warmly and enthusiastically invite the eminent researchers to take part in this special issue to enhance recent advancements in COVID-19 research.

We hope that collectively these papers will spur further research (and conversation) which we hope in turn will lead to changes in discoveries and development of new drugs to treat covid-19.

Drug Designing: Open Access Journal is using Editorial Tracking System to maintain quality and transparency to the author in the peer-review process. Review processing will be performed by the editorial board members of the Journal Drug Designing: Open Access or by Reviewers (outside experts in the field). Two independent reviewer’s approval (Minimum reviewer’s approval) followed by editor approval is obligatory for acceptance of any manuscript excluding an editorial.

Editorial tracking submission: https://www.longdom.org/submissions/drug-designing-open-access.html

Media Contact
Nancy Ella
Editor Board
Drug Designing: Open Access
drugdesign@eclinicalsci.org